016 Molecular analysis of treatment-refractory pityriasis rubra pilaris uncovers an IL-1 signature with therapeutic proof-of-concept of the anti-IL-1 biological anakinra

Abstract

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease phenotypically presenting features within the spectrum of psoriasis and atopic eczema. The pathogenesis is not fully understood but an activation of the interleukin (IL)-23 T-helper (Th) 17 axis has been shown, which currently present as a promising treatment option. Here we present an in depth molecular analysis of cytokine tissue profiling (nanostring) of patients with PRP (during and post-inflammation) comparing to plaque- type psoriasis, atopic dermatitis and healthy controls.